Canaccord raised the firm’s price target on Seres Therapeutics (MCRB) to $22 from $14 and keeps a Buy rating on the shares. The firm noted the FDA provided feedback on Seres’ proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions while also noting Seres is reducing staff by 25%, including August 2025 reductions, which should provide sufficient cash to fund operations into 2Q26.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics announces further constructive feedback from FDA on SER-155
- Seres Therapeutics’ Earnings Call: Progress Amid Challenges
- Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics
- Seres Therapeutics Reports Q2 2025 Financial Results
- Seres Therapeutics Reports Q2 Results and Leadership Change